10-K: Aptevo Therapeutics Inc. Reports Fiscal Year 2024 Results, Highlights Clinical Progress

Aptevo Therapeutics Inc. releases its 10-K filing, detailing its financial results for fiscal year 2024 and providing updates on its clinical-stage immunotherapy candidates.

Summary

• Aptevo Therapeutics Inc., a clinical-stage biotechnology company, has released its Form 10-K filing for the fiscal year ended December 31, 2024.
• The company is focused on developing novel immunotherapy candidates for cancer treatment, utilizing its ADAPTIR and ADAPTIR-FLEX platform technologies.
• Aptevo's clinical pipeline includes mipletamig, a CD3xCD123 T cell engager in Phase 1b/2 for acute myelogenous leukemia (AML), and ALG.APV-527, targeting 4-1BB and 5T4 for solid tumors, currently in Phase 1.
• Preclinical candidates APVO603, APVO711, and APVO442 are also under development.
• The company reported a net loss of $24.1 million for the year ended December 31, 2024, compared to a net loss of $17.4 million for the same period in 2023.
• As of December 31, 2024, Aptevo had cash and cash equivalents of $8.7 million.
• The company states that it will require additional funding to continue its business operations and clinical development programs.
• A going concern warning has been issued due to recurring losses and the need for additional capital.
• The company completed a Section 382 study and has concluded that it experienced an 'ownership change' as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the 'Code'), and thus the tax benefits of its pre-'ownership change' net operating loss carryforwards and certain other tax attributes will be subject to an annual limitation under Sections 382 and 383 of the Code.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive clinical updates, the financial results and going concern warning weigh heavily, resulting in a slightly negative outlook.

Positives

• RAINIER trial shows continued favorable efficacy and safety outcomes similar to those observed in the completed dose expansion phase of the trial.
• ALG.APV-527 demonstrated positive safety and tolerability across all cohorts.
• ALG.APV-527 could be measured in all patients and serum concentrations were proportional to the administered dose.
• Analysis of biomarkers in biopsies are consistent with immune activation in the tumor microenvironment.

Negatives

• The company has a history of losses and may not be profitable in the future.
• A going concern warning has been issued due to recurring losses and the need for additional capital.
• The company will require additional capital and may be unable to raise capital when needed or on acceptable terms.
• The results of current and planned preclinical studies and clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities.
• The company completed a Section 382 study and has concluded that it experienced an 'ownership change' as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the 'Code'), and thus the tax benefits of its pre-'ownership change' net operating loss carryforwards and certain other tax attributes will be subject to an annual limitation under Sections 382 and 383 of the Code.

Risks

• The company's common stock may be at risk for delisting from the Nasdaq Capital Market if it does not maintain compliance with Nasdaq's continued listing requirements.
• The company's success is dependent on its continued ability to attract, motivate, and retain key personnel.
• The company may not be successful in establishing and maintaining collaborations that leverage its capabilities in pursuit of developing and commercializing its product candidates.
• The company faces substantial competition, and its failure to effectively compete may prevent it from achieving significant market penetration for its product candidates, if approved.
• The company's business is affected by macroeconomic conditions, including rising and fluctuating inflation, interest rates, market volatility, economic uncertainty, and supply chain constraints.
• The company may be subject to periodic litigation, which could result in losses or unexpected expenditure of time and resources.

Future Outlook

Aptevo expects to continue to incur annual net operating losses for the foreseeable future and will require substantial resources over the next several years as it expands its efforts to discover, develop, and commercialize immunotherapeutic candidates.

Management Comments

• Management and board of directors have concluded that a substantial doubt is deemed to exist concerning the company's ability to continue as a going concern.

Industry Context

The document highlights the competitive landscape in the immuno-oncology market, noting the presence of both large and small molecule immune oncology products from various U.S.-based and foreign producers. It also mentions the increasing recognition of bispecific therapeutics as potent anti-cancer agents, with a growing number of FDA approvals in recent years.

Comparison to Industry Standards

• The document mentions competitors in the CD123-targeting and 4-1BB-targeting therapeutic areas, including Affimed, ImmunoGen, Novartis, and Boehringer Ingelheim.
• It states that Aptevo's therapies demonstrate competitive, and in some cases superior, profiles compared to industry benchmarks.
• The document notes that mipletamig may have high potency and activity at low doses with reduced cytokine release compared to other bispecifics targeting the same tumor antigen and CD3.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• Employees face uncertainty due to the company's financial situation and potential need for cost reductions.
• Customers (potential patients) may benefit from the development of new cancer therapies, but the company's financial situation could impact the timeline.
• Suppliers and creditors face increased risk due to the company's financial situation and potential need to extend payment terms.

Next Steps

• Continue clinical development of mipletamig in the RAINIER trial.
• Advance ALG.APV-527 for the treatment of solid tumors.
• Continue development and advancement of preclinical candidates APVO603, APVO442, and APVO711.
• Pursue collaborations with other biotechnology and pharmaceutical companies, academia, and non-governmental organizations to advance the product portfolio.

Key Dates

Keywords

Aptevo Therapeutics, immunotherapy, cancer, clinical trials, mipletamig, ALG.APV-527, ADAPTIR, ADAPTIR-FLEX, AML, biotechnology, financial results